Skip to main content
. 2021 Oct 27;81(3):335–343. doi: 10.1136/annrheumdis-2021-221276

Table 3.

Exposure-adjusted incidence rates of malignancies excluding NMSC by high-level term

High-level (group) term n EAIR (95% CI)
Respiratory and mediastinal neoplasms malignant and unspecified 26 0.17 (0.11 to 0.25)
Breast neoplasms malignant and unspecified (including nipple) 23 0.15 (0.10 to 0.23)
Gastrointestinal neoplasms malignant and unspecified 19 0.13 (0.08 to 0.20)
Reproductive neoplasms female malignant and unspecified 16 0.11 (0.06 to 0.17)
Reproductive neoplasms male malignant and unspecified (all reported cases were prostatic neoplasms) 10 0.07 (0.03 to 0.12)
Skin neoplasms malignant and unspecified (other than NMSC) 10 0.07 (0.03 to 0.12)
Renal and urinary tract neoplasms malignant and unspecified 9 0.06 (0.03 to 0.11)
Lymphomas non-Hodgkin’s B cell 6 0.04 (0.01 to 0.09)
Endocrine neoplasms malignant and unspecified 4 0.03 (0.01 to 0.07)
Metastases 3 0.02 (0.00 to 0.06)
Others* 15 0.10 (0.06 to 0.16)

*Others are all high-level group terms with 2 cases or fewer, including haematopoietic neoplasms (excluding leukaemias and lymphomas); hepatobiliary neoplasms malignant and unspecified; leukaemias; lymphomas non-Hodgkin’s T cell; lymphomas non-Hodgkin’s unspecified histology; miscellaneous and site unspecified neoplasms malignant and unspecified; neoplasm-related morbidities; nervous system neoplasms malignant and unspecified not elsewhere classified (NEC); not coded; ocular neoplasms; and soft tissue neoplasms malignant and unspecified.

EAIR, exposure-adjusted incidence rate; n, number of subjects in the specified category; NMSC, non-melanoma skin cancer.